Literature DB >> 9096197

Pharmacokinetics and bronchial diffusion of single daily dose amikacin in cystic fibrosis patients.

F Canis1, M O Husson, D Turck, P Vic, V Launay, S Ategbo, A Vincent, R J Courcol.   

Abstract

A single daily dose of amikacin 35 mg/kg by i.v. infusion over 30 min in 18 cystic fibrosis patients achieved mean serum peak and trough concentrations of 121.4 mg/L (+/- 37.3) and 0.88 mg/L (+/- 0.62), respectively. Pharmacokinetic parameters and bronchial diffusion of amikacin showed marked inter-patient variability. The highest concentrations in sputum were obtained at 2 h (10.95 +/- 7.55 mg/L) and decreased slowly to reach a mean concentration of 2.14 mg/L (range 0.2-3.8 mg/L) just before the following infusion. An increase in the body clearance of amikacin and a decrease in the volume of distribution according to age were observed.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9096197     DOI: 10.1093/jac/39.3.431

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  12 in total

Review 1.  Pharmacokinetic and Pharmacodynamic Optimization of Antibiotic Therapy in Cystic Fibrosis Patients: Current Evidences, Gaps in Knowledge and Future Directions.

Authors:  Charlotte Roy; Manon Launay; Sophie Magréault; Isabelle Sermet-Gaudelus; Vincent Jullien
Journal:  Clin Pharmacokinet       Date:  2021-01-24       Impact factor: 6.447

2.  Quantification of amikacin in bronchial epithelial lining fluid in neonates.

Authors:  C Tayman; M N El-Attug; E Adams; A Van Schepdael; A Debeer; K Allegaert; A Smits
Journal:  Antimicrob Agents Chemother       Date:  2011-06-27       Impact factor: 5.191

Review 3.  Pharmacokinetics and pharmacodynamics of aerosolized antibacterial agents in chronically infected cystic fibrosis patients.

Authors:  Axel Dalhoff
Journal:  Clin Microbiol Rev       Date:  2014-10       Impact factor: 26.132

4.  Liquid Chromatography Mass Spectrometry Detection of Antibiotic Agents in Sputum from Persons with Cystic Fibrosis.

Authors:  Tara Gallagher; Stefan Riedel; Joseph Kapcia; Lindsay J Caverly; Lisa Carmody; Linda M Kalikin; Junnan Lu; Joann Phan; Matthew Gargus; Miki Kagawa; Simon W Leemans; Jason A Rothman; Felix Grun; John J LiPuma; Katrine L Whiteson
Journal:  Antimicrob Agents Chemother       Date:  2021-01-20       Impact factor: 5.191

5.  Pharmacokinetics of tobramycin in adults with cystic fibrosis: implications for once-daily administration.

Authors:  P M Beringer; A A Vinks; R W Jelliffe; B J Shapiro
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

6.  The Role of PaFicT in Pseudomonas aeruginosa Persister Cell Formation.

Authors:  Dawson Fogen
Journal:  Int J Mol Cell Med       Date:  2022-06-06

Review 7.  Pharmacokinetic optimisation of antibacterial treatment in patients with cystic fibrosis. Current practice and suggestions for future directions.

Authors:  D J Touw; A A Vinks; J W Mouton; A M Horrevorts
Journal:  Clin Pharmacokinet       Date:  1998-12       Impact factor: 6.447

Review 8.  Antibiotic management of lung infections in cystic fibrosis. I. The microbiome, methicillin-resistant Staphylococcus aureus, gram-negative bacteria, and multiple infections.

Authors:  James F Chmiel; Timothy R Aksamit; Sanjay H Chotirmall; Elliott C Dasenbrook; J Stuart Elborn; John J LiPuma; Sarath C Ranganathan; Valerie J Waters; Felix A Ratjen
Journal:  Ann Am Thorac Soc       Date:  2014-09

9.  Differential antibiotic susceptibility of Mycobacterium abscessus variants in biofilms and macrophages compared to that of planktonic bacteria.

Authors:  Rebecca Greendyke; Thomas F Byrd
Journal:  Antimicrob Agents Chemother       Date:  2008-03-31       Impact factor: 5.191

10.  Efficacy and tolerability of extended-interval aminoglycoside administration in pediatric patients.

Authors:  Donna M Kraus; Manjunath P Pai; Keith A Rodvold
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.